Jon Petersen's questions to Grail Inc (GRAL) leadership • Q2 2025
Question
Jon Petersen of Piper Sandler inquired about early order trends from the Quest Diagnostics integration and sought commentary on the Galleri test's repeat testing rate and its trajectory.
Answer
CEO Bob Ragusa reported positive early results from the Quest integration, noting it reduces friction and that 7% of Q2 orders came through the platform from high-volume prescribers. He also expressed satisfaction with the repeat testing rate, which increased to 25% in Q2 from over 20% in Q1, viewing it as a strong indicator of product adoption for a non-reimbursed test.